Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
7 pending office actions • 4 art units • 7 examiners • 0 of 7 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days
Shanghai Junshi Biosciences Co. Ltd. is navigating 6 pending office actions within the Biotechnology & Pharmaceuticals sector. These actions are spread across 4 distinct art units, which requires the prosecution team to address a variety of technical examination standards. The workload is distributed among 6 distinct examiners, meaning no pending actions are currently being reviewed by the same person.
STEPHENS, AMELIA CAROLE is the busiest examiner for this portfolio with 1 pending action. This ratio between examiners and pending actions suggests a lack of examiner-specific concentration, requiring a broad strategy to handle the various perspectives across the 4 art units. The absence of overlapping examiners means that each response must be tailored to an individual's specific interpretation of biotechnology claims.
The diversity of art units involved indicates that the company is pursuing a wide range of pharmaceutical innovations. Legal counsel should prioritize individualized examiner interviews, as the current data shows no centralized point of influence within the USPTO. Success in this portfolio will depend on managing these 6 separate interactions with high precision and technical clarity.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §101 + other | 1 (14%) |
| §112 only | 1 (14%) |
| Double-patenting + other | 4 (57%) |
| Multi-statute (no §101) | 1 (14%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| STEPHENS, AMELIA CAROLE | 1 | 85.7% | +33.3% |
| CHATTIN, AMY MARIE | 1 | 73.6% | +44.0% |
| HAMA, JOANNE | 1 | 25.7% | +40.0% |
| LU, CHENG | 1 | 54.1% | +64.1% |
| ABBAS, SYED JARAR | 1 | 0.0% | +0.0% |
| BERHANE, SELAM | 1 | 58.4% | +56.7% |
| SALMON, KATHERINE D | 1 | 42.8% | +37.9% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 4 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18297983 | Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy | ABBAS, SYED JARAR | 15d |
| 18869686 | BIOMARKERS AND METHODS FOR TREATING NSCLC | STEPHENS, AMELIA CAROLE | — |
| 18562353 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY IN TREATING ESOPHAGEAL CANCER | HAMA, JOANNE | — |
| 18043204 | USE OF ANTI-PD-1 ANTIBODY IN TREATMENT OF NASOPHARYNGEAL CARCINOMA | BERHANE, SELAM | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18869686 | BIOMARKERS AND METHODS FOR TREATING NSCLC | STEPHENS, AMELIA CAROLE | — |
| 18686817 | ANTI-CLDN-18.2 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CHATTIN, AMY MARIE | — |
| 18562353 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY IN TREATING ESOPHAGEAL CANCER | HAMA, JOANNE | — |
| 18556885 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER | LU, CHENG | — |
| 18043204 | USE OF ANTI-PD-1 ANTIBODY IN TREATMENT OF NASOPHARYNGEAL CARCINOMA | BERHANE, SELAM | — |
| 17604058 | USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICAMENT FOR TREATING SOLID TUMORS | SALMON, KATHERINE D | — |
| Art Unit | Apps |
|---|---|
| 1642 | 1 |
| 1674 | 1 |
| 1675 | 1 |
| 1682 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18869686 | BIOMARKERS AND METHODS FOR TREATING NSCLC | STEPHENS, AMELIA CAROLE | — | §101§102§103§112 | Non-Final OA | — | Pending | Nov 26, 2024 |
| 18686817 | ANTI-CLDN-18.2 ANTIBODY-DRUG CONJUGATE AND USE THEREOF | CHATTIN, AMY MARIE | — | §112DP | Non-Final OA | — | Pending | Feb 26, 2024 |
| 18562353 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH CHEMOTHERAPY IN TREATING ESOPHAGEAL CANCER | HAMA, JOANNE | — | §102§103§112DP | Non-Final OA | — | Pending | Nov 20, 2023 |
| 18556885 | USE OF ANTI-PD-1 ANTIBODY IN COMBINATION WITH FIRST-LINE CHEMOTHERAPY IN TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER | LU, CHENG | 1642 | §103§112DP | Non-Final OA | — | Pending | Oct 23, 2023 |
| 18297983 | Compositions and Methods for Treating Solid Tumors with Anti-BTLA as Mono or Combination Therapy | ABBAS, SYED JARAR | 1674 | §102§103DP | Non-Final OA | 15d | Pending | Apr 10, 2023 |
| 18043204 | USE OF ANTI-PD-1 ANTIBODY IN TREATMENT OF NASOPHARYNGEAL CARCINOMA | BERHANE, SELAM | 1675 | §103§112 | Final Rejection | — | Pending | Feb 27, 2023 |
| 17604058 | USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICAMENT FOR TREATING SOLID TUMORS | SALMON, KATHERINE D | 1682 | §112 | Final Rejection | — | Pending | Oct 15, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial